{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Inside Germany’s biotech capital infrastructure and innovation engine","slug":"inside-germany-s-biotech-capital-infrastructure-and-innovation-engine","published_at":"2026-05-21T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/68216bacc58a087b74d0216d50f11d8f16f70d0a53ec603f8c51603fc26f8365/eyJlcGlzb2RlSWQiOiI0MjkxYzAyZi03OGVmLTRlMDEtYjVkZi1jMWQxYTFlMDM0NDAiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwZGMzOTBmYmM4ZDFlNDI2MmY1OTIxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTIwX18xNi0yMi04Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/68216bacc58a087b74d0216d50f11d8f16f70d0a53ec603f8c51603fc26f8365/eyJlcGlzb2RlSWQiOiI0MjkxYzAyZi03OGVmLTRlMDEtYjVkZi1jMWQxYTFlMDM0NDAiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwZGMzOTBmYmM4ZDFlNDI2MmY1OTIxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTIwX18xNi0yMi04Lm1wMyJ9.mp3","summary":"In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Regina Hodits , Managing Director, Angelini Ventures Sofia Ioannidou , VC Partner, Andera Life Sciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing dire…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1397,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}